Bone Health in Patients With Adrenal Adenomas and Hypercortisolism: A Multicenter Cross‐Sectional Study
- 7 October 2025
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 104 (2) , 103-112
Abstract
Objective: Data on bone health in patients with mild autonomous cortisol secretion (MACS) are limited and heterogenous. We sought to assess the prevalence of osteoporosis and symptomatic fragility fractures in patients with adrenal adenomas and hypercortisolism, and explore associations with the degree of cortisol excess and frailty. Design: This multicenter cross ‐sectional study involved prospective enrollment of adults with nonfunctioning adrenal adenomas (NFA), MACS, Cushing syndrome (CS) and referent subjects without adrenal disorders during the study period (January 2019–September 2022). All participants completed a bone health questionnaire at enrollment and had dual‐energy X ‐ray absorptiometry bone mineral density assessment within 12‐months. Final analyses were adjusted for age, sex, body mass index, smoking status, alcohol use. Results: Participants included 117 with NFA (median age 62 years, 80% women), 191 with MACS (median age 63 years, 74% women), 62 with CS (median age 50 years, 92% women), and 101 referent subjects (median age 59 years, 47% women). Both patients with CS (OR: 3.0, 95% CI: 1.1–8.3) and MACS (OR: 2.2, 95% CI: 1.9–4.9) had a higher prevalence of osteoporosis when compared to referents. Among patients with MACS, only those with post 1‐mg dexamethasone suppression test (post‐1mg‐DST) cortisol > 83 nmol/L had a higher prevalence of osteoporosis when compared to referents (OR: 3.2, 95% CI: 1.4–7.5) and NFA (OR: 2.2, 95% CI: 1.1–4.4). For clinical fragility fractures, only patients with CS showed an increased prevalence when compared to referents (OR: 6.1, 95% CI: 1.7–26.4) and NFA (OR: 3.8, 95% CI: 1.3–11.2). Prevalence of clinical fragility fractures was similar to referents in patients with MACS (OR: 1.8, 95% CI: 0.6–6.9) and NFA (OR: 1.5, 95% CI: 0.4–6.1), and was not associated with post‐1mg‐DST cortisol or frailty in the MACS and NFA groups. Conclusion: Patients with CS, and those with MACS and post‐1mg‐DST cortisol > 83 nmol/L, exhibited a higher burden of osteoporosis. However, only CS was associated with an elevated risk of symptomatic fragility fractures.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
This publication has 18 references indexed in Scilit:
- Predicting fragility fractures based on frailty and bone mineral density among rural community-dwelling older adultsEuropean Journal of Endocrinology, 2024
- Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysisEuropean Journal of Endocrinology, 2023
- High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolmentEuropean Journal of Endocrinology, 2023
- European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal TumorsEuropean Journal of Endocrinology, 2023
- Mild autonomous cortisol secretion in adrenal incidentalomas and risk of fragility fractures: a large cross-sectional studyEuropean Journal of Endocrinology, 2023
- Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort studyThe Lancet Diabetes & Endocrinology, 2022
- The clinician’s guide to prevention and treatment of osteoporosisOsteoporosis International, 2022
- Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and PediatricsJournal of Clinical Densitometry, 2019
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO reportOsteoporosis International, 1994